CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia A and B and rare bleeding disorders (RBD). Fitusiran is designed to lower levels of AT with the goal of promoting sufficient thrombin generation to restore hemostasis and prevent bleeding in patients with hemophilia and RBD. These new data will be presented in an oral presentation at the World Federation of Hemophilia (WFH) 2016 World Congress, on Wednesday, July 27, 2016 in Orlando, Florida. Due to an inadvertent posting for a short period this morning of a draft version of the presentation on the WFH website, the Company will now host a conference call today, Monday, July 25, at 1:00 pm ET, to discuss these results.
New clinical data showed that once-monthly subcutaneous administration of fitusiran achieved dose-dependent lowering of AT and increases in thrombin generation, resulting in a median estimated annualized bleeding rate (ABR) of zero in evaluable patients with hemophilia A or B without inhibitors (N=17). In addition, data from an initial cohort of hemophilia patients with inhibitors (N=6) demonstrated AT lowering, increased thrombin generation, and preliminary evidence for reduced bleeding. Importantly, fitusiran was found to be generally well tolerated to date in patients with and without inhibitors, including no thromboembolic events. Finally, the Company announced that it now plans to initiate fitusiran pivotal studies in people with hemophilia with and without inhibitors in early 2017.
“As a once-monthly, fixed dose, subcutaneous prophylactic treatment option that could be shown to provide durable and consistent bleed prevention, fitusiran has the potential to transform the management of hemophilia and RBD, including patients with inhibitors. We believe these new data bring us closer to realizing that potential, as our exploratory analysis indicates that fitusiran can achieve a median estimated ABR of zero in patients with hemophilia A or B without inhibitors,” said Akin Akinc, Ph.D., Vice President and General Manager, Fitusiran. “Moreover, we believe our preliminary data in the first cohort of inhibitor patients receiving a low monthly subcutaneous fixed dose of 50 mg are promising, and we look forward to additional data at higher fitusiran doses in this patient sub-group with very high unmet need. Importantly, we continue to be encouraged by the tolerability profile for fitusiran.”
New results were presented from Part C (N=18) and Part D (N=6) of the ongoing Phase 1 study, and include all available data as of the data transfer up to July 11, 2016. Part C evaluated a monthly subcutaneous regimen at doses ranging from 225 micrograms per kilogram (mcg/kg) to 1800 mcg/kg, and also includes a cohort of six patients that received a fixed dose of 80 mg. Part D is evaluating monthly subcutaneous dosing in people with hemophilia A and B with inhibitors, and is designed to enroll up to a total of 18 patients. The first cohort of six patients with inhibitors received a 50 mg fixed, once-monthly, subcutaneous dose regimen. The second cohort has completed enrollment with six inhibitor patients receiving an 80 mg fixed, once-monthly, subcutaneous dose regimen.
Phase 1 Part C Interim Study Results in Hemophilia A or B without
Inhibitors
Treatment with fitusiran resulted in potent,
dose-dependent, and statistically significant lowering of AT. At the 80
mg fixed monthly dose, fitusiran achieved 87 ± 1 percent mean maximal AT
lowering with low inter-patient variability. The association between AT
lowering and increased thrombin generation was assessed in a post hoc
exploratory analysis in which AT lowering was grouped by 25 percent
increments for completed patients in Parts B (N=12) and C (N=17) of the
study. In the highest quartile of greater than or equal to 75 percent AT
lowering (N=16), fitusiran administration resulted in mean increases in
thrombin generation of approximately 290 percent relative to baseline (p
less than 0.001, as compared to the lowest AT lowering quartile).
Furthermore, there was a statistically significant, AT
lowering-dependent reduction in bleeding frequency, with the greatest
effect seen at greater than or equal to 75 percent AT lowering (p less
than 0.05, based on a negative binomial regression model). These data
support the therapeutic hypothesis that AT lowering of 75 percent or
greater is associated with attenuation of the hemophilia phenotype in
non-inhibitor patients.
To obtain a more comprehensive assessment of potential fitusiran effects on bleeding, a post hoc analysis was performed in evaluable patients from all five cohorts in Part C (N=17). Specifically, bleed events that occurred over the six month period prior to study entry (based on review of medical records) and bleed events that were assessed prospectively during days 0-28 following the initial fitusiran dose (the “onset period”) were compared with bleed events that occurred beyond day 29 up to day 112 (the “observation period”), the time period during which fitusiran achieves its therapeutic pharmacodynamic effect. Median estimated ABR values were determined accordingly. In addition, bleed events classified as “spontaneous” were analyzed separately to determine the estimated annualized spontaneous bleeding rate (AsBR).
Prior to study entry, evaluable patients (N=17) had an estimated median ABR of 28 for patients receiving on-demand factor therapy (N=4) and an estimated median ABR of two for patients receiving prophylactic factor therapy (N=13). During the prospectively monitored “onset period” interval, the estimated median ABR was 13 among all evaluable patients. In contrast, during the observation period, fitusiran administration achieved an estimated median ABR of zero. In all Part C dose cohorts during the observation period, the majority of patients (9 of 17; 53 percent) were bleed-free, and 82 percent of patients reported no spontaneous bleeds. In the 80 mg fixed dose cohort, the estimated median ABR of zero compared favorably with the pre-study ABR of 6 for the same patients when they were receiving prophylactic replacement factor therapy. While not based on direct comparative studies, the median estimated ABR achieved with once-monthly, subcutaneous fitusiran compares favorably to the range of median ABR values of zero to four reported in clinical studies of frequent prophylactic intravenous infusions of recombinant Factors VIII or IX.
Initial Phase 1 Part D Study Results in Hemophilia A or B Patients
with Inhibitors
Patients with hemophilia A or B with inhibitors
were enrolled in the initial Part D dose cohort. Prior to study entry,
all patients utilized bypass agents, including recombinant Factor VIIa
and activated prothrombin complex concentrate (aPCC), to manage their
bleeds, and had a notably high pre-study ABR of up to 80, based on
review of medical records.
In order to obtain an initial experience with fitusiran, the first cohort (N=6) of inhibitor patients received a once-monthly, fixed subcutaneous dose of 50 mg. Fitusiran achieved a mean maximal AT lowering of 81 ± 2 percent and a mean maximal thrombin generation increase of approximately 368 percent, comparable to results observed from Part C in non-inhibitor patients at similar doses. In addition, preliminary evidence for reduced bleeding was observed, with a 49-100 percent reduction in estimated ABR during the observation period compared with pre-study values. Dose escalation has occurred, and the next cohort of inhibitor patients has been fully enrolled with once-monthly subcutaneous dosing at 80 mg (N=6). The Company expects to present additional data from inhibitor patients in Part D of the study in late 2016.
Interim Phase 1 Study Safety Results
As of the data transfer
on July 11, 2016, fitusiran continues to be generally well tolerated in
patients with hemophilia with or without inhibitors (N=31, with five
patients participating in both Parts B and C). There have been no
serious adverse events (SAEs) related to study drug, and no
thromboembolic events or laboratory evidence (based on D-dimer, platelet
count, fibrinogen, and/or PT/INR) of pathologic clot formation. All
bleeds were successfully managed with standard replacement factor or
bypass agent administration. One non-inhibitor patient in Part C at the
80 mg fixed dose cohort discontinued due to an adverse event considered
severe and possibly related to study drug per. This event was described
as non-cardiac chest pain and was accompanied by transient elevations of
ALT (10x upper limit of normal, ULN), AST (8x ULN), C-reactive protein,
and D-dimer, without increase in total bilirubin. Extensive evaluation
was unremarkable, and venous thromboembolism was excluded by serial CT
angiograms and liver and lower extremity ultrasound. This patient’s
event resolved with symptomatic management, including antacids and
analgesics. Eleven patients (35 percent) reported mild, drug-related
injection site reactions (ISRs), which were mostly pain or erythema at
the injection site. Additional AEs reported in greater than or equal to
10 percent of patients included upper respiratory tract infection (10
percent) and arthralgia (10 percent); the majority of these AEs were
mild or moderate in severity. With the exception of the case noted
above, there were no other clinically significant drug related changes
in laboratory parameters. Finally, there have been no instances of
anti-drug antibody formation to fitusiran.
Additional Data and Development Plans
“Turning to our
development plans, we’ve completed constructive initial discussions with
regulatory authorities and as an update to previous guidance, we now
plan to initiate our Phase 3 studies in patients with and without
inhibitors in early 2017 following completion of the second inhibitor
patient dose cohort in the Phase 1 study,” Dr. Akinc added. “Moreover,
we plan on presenting additional data later this year, including
additional results from inhibitor patients and initial data from the
ongoing Phase 1/2 open-label extension study, where patients have now
received up to 13 monthly doses of fitusiran.”
Alnylam plans to report additional data from fitusiran studies in late 2016. These data are expected to include additional results from Part D of the ongoing Phase 1 study and initial results from the Phase 1/2 open-label extension (OLE) study. Twenty-one patients who have completed treatment in the Phase 1 study have now rolled over to the OLE study, where they are receiving monthly fitusiran administration. Additional patients are expected to enroll in the OLE study as they become eligible.
To view the clinical results presented by Alnylam at the WFH meeting, please visit www.alnylam.com/capella.
Conference Call Information
Alnylam management will discuss
these data in a webcast conference call today, Monday, July
25, at 1:00 p.m. ET. A slide presentation will also be
available on the Investors page of the company's website, www.alnylam.com,
to accompany the conference call. To access the call, please dial
877-312-7507 (domestic) or 631-813-4828 (international) five minutes
prior to the start time and refer to conference ID 51834298. A replay of
the call will be available at 3:00 p.m. ET. To access the replay, please
dial 855-859-2056 (domestic) or 404-537-3406 (international), and refer
to conference ID 51834298.
About the Fitusiran Phase 1 Study
The ongoing Phase 1 trial
of fitusiran is being conducted in United States,
Bulgaria, Russia, Switzerland, and the U.K. as a single- and multi-dose,
dose-escalation study comprised of four parts. Part A – which is
complete – was a randomized, single-blind, placebo-controlled,
single-dose, dose-escalation study (N=4 per cohort; 3:1 randomization of
fitusiran:placebo) in healthy volunteers. This part of the study was
completed after the first dose cohort received a single subcutaneous
dose of fitusiran at 30 mcg/kg. Part B of the study – which is also
complete – was an open-label, multi-dose, dose-escalation study that
enrolled 12 patients with severe hemophilia A or B. Patients in Part B
received three weekly subcutaneous injections of fitusiran at doses of
15, 45, or 75 mcg/kg. Part C of the study – which has completed dosing –
is an open-label, multi-dose, dose escalation study that enrolled 18
patients with moderate or severe hemophilia A or B without inhibitors.
Twelve patients in Part C received three monthly subcutaneous doses of
fitusiran at doses of 225, 450, 900, or 1800 mcg/kg. In addition, six
patients in Part C received three fixed monthly subcutaneous doses of
fitusiran at 80 mg. Part D of the study is designed to enroll up to 18
patients with inhibitors. Patients in Part D will receive three fixed
monthly subcutaneous doses of fitusiran at 50 mg or 80 mg. The primary
objective of Parts B, C, and D of the study is to evaluate the safety
and tolerability of multiple doses of subcutaneously administered
fitusiran in patients with hemophilia, with and without inhibitors.
Secondary objectives include assessment of clinical activity as
determined by lowering of circulating AT levels and increase in thrombin
generation at pharmacologic doses of fitusiran. In addition, exploratory
analyses of bleeding are being performed. In the U.K., enrollment has
been aided by the Southern Academic Coagulation Consortium (SACC).
Fitusiran is an investigational compound, currently in early stage clinical development. The safety and efficacy of fitusiran have not been evaluated by the U.S. Food and Drug Administration or any other health authority.
About Hemophilia and Rare Bleeding Disorders
Hemophilia is a
bleeding disorder characterized by insufficient thrombin generation
following hemostatic challenge and resulting in recurrent bleeds into
joints, muscles, and other internal organs. There are approximately
200,000 diagnosed patients with hemophilia worldwide. Hemophilia A is
defined by loss-of-function mutations in Factor VIII, and represents
approximately 80 percent of the hemophilia population. Hemophilia B, is
defined by loss-of-function mutations in Factor IX, and represents
approximately 20 percent of the hemophilia population. Other Rare
Bleeding Disorders (RBD) are defined by deficiencies of blood
coagulation factors, including Factors II, V, VII, X, and XI. There are
an estimated 1,000 persons worldwide with a severe bleeding phenotype
because of these conditions. The goal of treatment for persons living
with hemophilia is to prevent bleeding, establish prompt management of
bleeds, and manage the complications of bleeding and treatment. Current
guidelines recommend management of hemophilia with regular intravenous
infusions of recombinant or human-derived clotting factors. However, the
most serious treatment-related complication is the development of
antibodies, known as "inhibitors", to replacement factor. Inhibitor
development can occur in both hemophilia A and hemophilia B, impacting
as many as one-third of people with severe hemophilia A, and persons in
this ‘inhibitor' subset become refractory to standard replacement
therapy. There exists a significant need for novel therapeutics to treat
people living with hemophilia.
About Antithrombin (AT)
Antithrombin (AT, also known as
"antithrombin III" and "SERPINC1") is a liver-expressed plasma protein
and member of the "serpin" family of proteins that acts by inactivating
thrombin and other coagulation factors. AT plays a key role in normal
hemostasis by helping to limit the process of fibrin clot formation.
However, in hemophilia, insufficient thrombin generation results in
impaired fibrin clot formation. Lowering AT in the hemophilia setting
may promote the generation of sufficient levels of thrombin needed to
form an effective fibrin clot and prevent bleeding. This rationale is
supported by human genetic data suggesting that co-inheritance of
thrombophilic mutations, including AT deficiency, may ameliorate
bleeding in hemophilia. Lowering of AT is a unique and innovative
strategy for restoring hemostasis in people with hemophilia.
Sanofi Genzyme Alliance
In January 2014, Alnylam and Sanofi
Genzyme, the specialty care global business unit of Sanofi, formed an
alliance to accelerate and expand the development and commercialization
of RNAi therapeutics across the world. The alliance is structured as a
multi-product geographic alliance in the field of rare diseases. Alnylam
retains product rights in North America and Western Europe, while Sanofi
Genzyme obtained the right to access certain programs in Alnylam's
current and future Genetic Medicines pipeline in the rest of the world
(ROW) through the end of 2019, together with certain broader
co-development/co-commercialization rights and global product rights for
certain products. In the case of fitusiran, Sanofi Genzyme has elected
to opt into the program for its ROW rights, while retaining its further
opt-in right to co-develop and co-promote fitusiran with Alnylam
in North America and Western Europe, subject to certain restrictions.
About GalNAc Conjugates and Enhanced Stabilization Chemistry
(ESC)-GalNAc Conjugates
GalNAc-siRNA conjugates are a
proprietary Alnylam delivery platform and are designed to achieve
targeted delivery of RNAi therapeutics to hepatocytes through uptake by
the asialoglycoprotein receptor. Alnylam's Enhanced Stabilization
Chemistry (ESC)-GalNAc-conjugate technology enables subcutaneous dosing
with increased potency and durability, and a wide therapeutic index.
This delivery platform is being employed in nearly all of Alnylam's
pipeline programs, including programs in clinical development.
About RNAi
RNAi (RNA interference) is a revolution in
biology, representing a breakthrough in understanding how genes are
turned on and off in cells, and a completely new approach to drug
discovery and development. Its discovery has been heralded as "a major
scientific breakthrough that happens once every decade or so," and
represents one of the most promising and rapidly advancing frontiers in
biology and drug discovery today which was awarded the 2006 Nobel Prize
for Physiology or Medicine. RNAi is a natural process of gene silencing
that occurs in organisms ranging from plants to mammals. By harnessing
the natural biological process of RNAi occurring in our cells, the
creation of a major new class of medicines, known as RNAi therapeutics,
is on the horizon. Small interfering RNA (siRNA), the molecules that
mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target
the cause of diseases by potently silencing specific mRNAs, thereby
preventing disease-causing proteins from being made. RNAi therapeutics
have the potential to treat disease and help patients in a fundamentally
new way.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical
company developing novel therapeutics based on RNA interference, or
RNAi. The company is leading the translation of RNAi as a new class of
innovative medicines. Alnylam's pipeline of investigational RNAi
therapeutics is focused in 3 Strategic Therapeutic Areas (STArs):
Genetic Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of
RNAi therapeutics toward genetically validated, liver-expressed disease
targets for unmet needs in cardiovascular and metabolic diseases; and
Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance
for the advancement and commercialization of RNAi therapeutics as a
whole new class of innovative medicines. Specifically, by the end of
2020, Alnylam expects to achieve a company profile with 3 marketed
products, 10 RNAi therapeutic clinical programs – including 4 in late
stages of development – across its 3 STArs. The company's demonstrated
commitment to RNAi therapeutics has enabled it to form major alliances
with leading companies including Ionis, Novartis, Roche, Takeda, Merck,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a company
focused on discovery, development, and commercialization of microRNA
therapeutics. Alnylam scientists and collaborators have published their
research on RNAi therapeutics in over 200 peer-reviewed papers,
including many in the world's top scientific journals such as Nature,
Nature Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains
headquarters in Cambridge, Massachusetts. For more information about
Alnylam's pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.
Alnylam Forward Looking Statements
Various statements in
this release concerning Alnylam's future expectations, plans and
prospects, including without limitation, Alnylam's views with respect to
the potential for RNAi investigational therapeutics, including fitusiran
(ALN-AT3), the potential implications of reported results from its
ongoing Phase 1 trial, its expectations regarding the timing of clinical
studies, including its updated guidance regarding the initiation of
pivotal Phase 3 studies, and the expected timing for the presentation of
clinical data from fitusiran studies, its expectations regarding its
STAr pipeline growth strategy, and its plans regarding commercialization
of RNAi therapeutics, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including, without limitation, Alnylam's
ability to discover and develop novel drug candidates and delivery
approaches, successfully demonstrate the efficacy and safety of its drug
candidates, the pre-clinical and clinical results for its product
candidates, which may not be replicated or continue to occur in other
subjects or in additional studies or otherwise support further
development of product candidates, actions or advice of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials, obtaining, maintaining and protecting intellectual
property, Alnylam's ability to enforce its patents against infringers
and defend its patent portfolio against challenges from third parties,
obtaining regulatory approval for products, competition from others
using technology similar to Alnylam's and others developing products for
similar uses, Alnylam's ability to manage operating expenses, Alnylam's
ability to obtain additional funding to support its business activities
and establish and maintain strategic business alliances and new business
initiatives, Alnylam's dependence on third parties for development,
manufacture, marketing, sales and distribution of products, the outcome
of litigation, and unexpected expenditures, as well as those risks more
fully discussed in the "Risk Factors" filed with Alnylam's most recent
Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission (SEC) and in other filings that Alnylam makes with the SEC.
In addition, any forward-looking statements represent Alnylam's views
only as of today and should not be relied upon as representing its views
as of any subsequent date. Alnylam explicitly disclaims any obligation
to update any forward-looking statements.